Clinical performance of artificial intelligence-powered annotation of tumor cell PD-L1 expression for treatment of immune-checkpoint inhibitor (ICI) in advanced non-small cell lung cancer (NSCLC).

被引：2

作者：

Kim, Hyojin

Choi, Sangjoon

Kim, Seokhwi

Aum, Jaehong

Pereira, Sergio

Park, Seonwook

Ma, Minuk

Shin, Seunghwan

Paeng, Kyunghyun

Yoo, Donggeun

Jung, Wonkyung

Ock, Chan-Young

Lee, Se-Hoon

Chung, Jin-haeng

Choi, Yoon-La

Mok, Tony S. K.

机构：

[1] Seoul Natl Univ, Bundang Hosp, Dept Pathol, Seongnam, South Korea

[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol & Translat Genom, Seoul, South Korea

[3] Ajou Univ, Sch Med, Dept Pathol, Suwon, South Korea

[4] Lunit Inc, Seoul, South Korea

[5] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul, South Korea

[6] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol & Translat Med, Seoul, South Korea

[7] Chinese Univ Hong Kong, State Key Lab Translat Oncol, Hong Kong, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.9026

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9026

引用

页数：2

共 50 条

[21] Chronic immune checkpoint inhibitor (ICI) pneumonitis in patients (pts) with non-small cell lung cancer (NSCLC).
Stuart, Jessica
Ricciuti, Biagio
Alessi, Joao Victor Machado
Nishino, Mizuki
Awad, Mark M.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[22] Cost Effectiveness of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Relative to PD-L1 Expression
Aguiar, Pedro, Jr.
De Mello, Ramon
Tadokoro, Hakaru
Santoro, Ilka
Babiker, Hani
Avancha, Kiran
Gutierres, Barbara
Barreto, Carmelia
Lopes, Gilberto
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S169 - S170
[23] Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer
Sakamoto, Mandy
Jimeno, Antonio
DRUGS OF TODAY, 2023, 59 (03) : 169 - 177
[24] Biomarkers of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Beyond PD-L1
Cabezon-Gutierrez, Luis
Custodio-Cabello, Sara
Palka-Kotlowska, Magda
Alonso-Viteri, Soledad
Khosravi-Shahi, Parham
CLINICAL LUNG CANCER, 2021, 22 (05) : 381 - 389
[25] DYNAMIC CHANGE OF PD-L1 EXPRESSION ON EXTRACELLULAR VESICLES PREDICTS RESPONSE TO IMMUNE-CHECKPOINT INHIBITORS IN NON-SMALL CELL LUNG CANCER PATIENTS
Perez, Diego de Miguel
Russo, Alessandro
Gunasekaran, Muthukumar
Cardona, Andres
Lapidus, Rena
Cooper, Brandon
Kaushal, Sunjay
Peterson, Christine
Colen, Rivka
Naing, Aung
Adamo, Vincenzo
Rolfo, Christian
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A17 - A18
[26] Patterns of response and progression with immune-checkpoint inhibitor combinations in advanced non-small cell lung cancer
Brown, Lauren
Ahn, Julie
Gee, Harriet
Nagrial, Adnan
Hau, Eric
Da Silva, Ines Pires
RESPIROLOGY, 2023, 28 : 18 - 19
[27] The Role of Serum Proteomic Signature in Predicting Survival in PD-L1 Low Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor (ICI)
Kim, L.
Oh, Y.
Yoon, S. M.
Park, J. H.
Chae, Y. K.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S152 - S153
[28] Association of PD-L1 expression with hotspot mutations in non-small cell lung cancer (NSCLC).
Wan, Renping
Zhang, Xiaoni
Qu, Hongyue
Li, Hui
Li, Yingmei
Xu, Mingyan
Xiao, Yun
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[29] Serum immune checkpoint biomarkers as predictors of response to anti-PD-1/PD-L1 treatment in non-small cell lung cancer (NSCLC) patients
Raza, A.
Mohsin, R.
Kanbour, A.
Vijayakar, S.
Philip, A.
Tauro, M. A.
Sherif, S.
Merhi, M.
Inchakalody, V.
Gul, A. R. Zar
Al Homsi, M. U.
Dermime, S.
ANNALS OF ONCOLOGY, 2021, 32 : S1380 - S1380
[30] PD-L1 expression and survival in patients with non-small cell lung cancer (NSCLC) in Korea
Sun, Jong-Mu
Zhou, Wei
Choi, Yoon-La
Choi, So-Jung
Kim, Se Eun
Wang, Zhen
Dolled-Filhart, Marisa
Emancipator, Kenneth
Weiner, Russell
Park, Minjin
Kim, Hong Kwan
Choi, Yong Soo
Shim, Young Mog
Kim, Jhingook
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

← 1 2 3 4 5 →